Building awareness is built on validation. Raising a round of capital is a 1:1 indicator of financial interest. Showcasing industry partnerships offers another key validator, and often interesting content for reporters to cover. That’s the case with this strategic placement for AI-driven robotic software client, Olis Robotics.
Artificial Intelligence and Machine Learning make news pieces like this ZDNet story our s2s Public Relations team landed for a client, not because of the often flash-over-substance #Ai and #ML hype, but what these technologies empower people to do… like, say, repair dead and dying satellites in orbit.
Read about the latest research into the cannabis genome produced by our client Phase Genomics and placed into the Genetic Literacy Project, with its reach into hundreds of thousands of those academia, research, and just plain science enthusiasts each month. Click on the link in the caption to read more:
Colony collapse disorder has been the scourge of U.S. beekeepers for more than a decade, contributing to a 30-40 percent plunge in commercial honey bee colonies since 2006. Read the rest right here: zmescience.com/science/biology/saving-the-honey-bee-can-new-genomic-clues-help-solve-the-colony-collapse-mystery
Nu-Med Plus, a medtech firm based in Utah, has developed a range of smart delivery devices for inhaled nitric oxide delivery, including a miniaturized unit that can operate in a doctor’s office. The innovation has been possible as parts of the drug patent for nitric oxide have been invalidated, meaning that the cost of the treatment […]
Angel investing is a tricky game. Supporting a startup just getting off the ground takes a lot of work. But after several years spent as a venture capitalist in the Bay Area, Susan Preston, now the managing member at Seattle’s SeaChange Fund, returned to the Pacific Northwest with an idea for how to spot sound […]
Every patient’s cancer is unique and every patient responds to cancer drugs differently. But right now, all patients with the same kind of cancer are treated with the same drugs. SEngine Precision Medicine is hoping to change that with new platform, called PARIS, that grows and analyzes a patient’s cancer cells to figure out which drugs […]
We’re proud to have cultivated the speaking engagement for Phase Genomics. CEO Ivan Liachko will present on the convergence of technology and the life sciences on June 12th in Seattle, alongside other biotech innovators such as Adaptive Biotechnologies and Silverback Therapeutics. Find the details and join us here: https://www.xconomy.com/whats-hot-in-seattle-biotech/speakers/
Scientists from Cure First and SEngine Precision Medicine discover common link in 28% of all cancers Read the story here
SEngine Precision Medicine CEO Dr. Carla Grandori showcases SEngine’s scientific edge in functional precision oncology: